文献速递临床试验与 GCP

低剂量地高辛在射血分数降低或轻度降低的心力衰竭患者中的随机对照试验

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.
PubMed 文献 · Nat Med · 2026-05-10

DECISION试验为双盲安慰剂对照研究,纳入1001例有症状的慢性心力衰竭且左室射血分数≤50%的患者,随机接受低剂量地高辛(目标血清浓度0.5-0.9 ng/ml)或安慰剂。中位随访36.5个月,主要复合终点(总心力衰竭恶化事件和心血管死亡)两组无显著差异(率比0.81;95%CI 0.61-1.07,P=0.133)。低剂量地高辛耐受性良好,未显著减少复合终点事件。

要点

  • 低剂量地高辛未显著降低心力衰竭恶化事件或心血管死亡的复合终点。
  • 地高辛组与安慰剂组主要终点率比0.81(95%CI 0.61-1.07,P=0.133)。
  • 低剂量地高辛一般耐受良好且安全,男女结果相似。

核心结论

  • 在射血分数降低或轻度降低的心力衰竭患者中,低剂量地高辛未显著减少心力衰竭恶化事件或心血管死亡的复合终点。

研究设计与样本

  • DECISION试验为双盲、安慰剂对照随机对照试验,纳入1001例有症状的慢性心力衰竭且左室射血分数≤50%的患者。
  • 患者随机接受低剂量地高辛(目标血清浓度0.5-0.9 ng/ml)或安慰剂,平均年龄72±9岁,28%为女性,29%合并心房颤动。

主要发现

  • 中位随访36.5个月,地高辛组500例中131例发生238次主要终点事件,安慰剂组501例中152例发生291次(率比0.81;95%CI 0.61-1.07,P=0.133)。
  • 心力衰竭恶化事件总数在地高辛组和安慰剂组分别为155次和203次(率比0.76;95%CI 0.54-1.05)。
  • 心血管死亡在地高辛组和安慰剂组分别发生于83例(17%)和88例(18%)(风险比0.93;95%CI 0.69-1.26)。
  • 低剂量地高辛一般耐受良好且安全,男女结果相似。

临床怎么用

  • 对于射血分数降低或轻度降低的心力衰竭患者,低剂量地高辛未显示显著减少心力衰竭恶化事件或心血管死亡。
  • 低剂量地高辛在此人群中耐受良好且安全,但需结合个体情况权衡使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Digoxin is the oldest drug in cardiovascular medicine, but its value in the current management of heart failure is unclear. Earlier studies have suggested that low-dose digoxin might be beneficial, but evidence from rigorous randomized clinical trials is lacking. In this double-blind, placebo-controlled trial (the DECISION trial), 1,001 patients with symptomatic chronic heart failure and a left ventricular ejection fraction of 50% or less were randomized to low-dose digoxin or placebo, with a target serum digoxin concentration of 0.5-0.9 ng ml-1. The mean age of the participants was 72 ± 9 years, 28% were women and 29% had atrial fibrillation. The primary outcome was a composite of total worsening heart failure events, defined as total hospitalizations or total urgent hospital visits for worsening heart failure and cardiovascular mortality. Over a median follow-up of 36.5 months, 238 primary-outcome events occurred in 131 of 500 patients in the digoxin group, and 291 primary-outcome events in 152 of 501 patients occurred in the placebo group (rate ratio 0.81; 95% confidence interval (CI) 0.61-1.07, P = 0.133). The total number of worsening heart failure events was 155 and 203 in the digoxin and placebo groups, respectively (rate ratio 0.76, 95% CI 0.54-1.05) and cardiovascular mortality occurred in 83 patients (17%) and 88 (18%) in the digoxin and placebo groups, respectively (hazard ratio 0.93, 95% CI 0.69-1.26). Low-dose digoxin was generally well tolerated and safe, and results were similar between men and women. The results of this trial indicate that in patients with heart failure and reduced or mildly reduced ejection fraction, low-dose digoxin did not significantly reduce the composite endpoint of total worsening heart failure events or cardiovascular mortality. ClinicalTrials.gov registration: NCT03783429 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. van Veldhuisen DJ, Rienstra M, Mosterd A, et al. Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial. Nat Med. 2026. PMID: 42108270. doi:10.1038/s41591-026-04406-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。